Vanguard Portfolio Management
JBIO

Vanguard Portfolio Management’s Jade Biosciences JBIO Stock Holding History

Vanguard Portfolio Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Buy
461,528
+250,209
+118% +$5.22M ﹤0.01% 2190
2026
Q1 		$2.97M Buy
+211,319
New +$3.06M ﹤0.01% 2486

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management's JBIO Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Jade Biosciences (JBIO) stake by 118% in Q2 2026, buying an estimated $5.22M and bringing the position to 461,528 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

Vanguard Portfolio Management first reported a position in JBIO in Q1 2026 and has held it in 2 quarters since. 153 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Vanguard Portfolio Management held 461,528 shares of Jade Biosciences worth $10.3M as of Q2 2026.
  • Vanguard Portfolio Management bought 250,209 Jade Biosciences shares in Q2 2026, an estimated $5.22M.
  • Jade Biosciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2190 holding.
  • Vanguard Portfolio Management first reported a position in Jade Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 153 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.